Last updated: February 19, 2026
Nefazodone hydrochloride, marketed historically as Serzone, is an antidepressant originally approved by the U.S. Food and Drug Administration (FDA) in 1994. It functions as a serotonin antagonist and reuptake inhibitor (SARI). Its market presence has declined markedly due to safety concerns, notably hepatotoxicity, leading to voluntary removal from many markets by its manufacturer. Current market activity is limited, with minimal sales and little R&D investment, but historical and potential future factors influence its financial trajectory.
Historical Market and Regulatory Context
| Year |
Development & Approval |
Market Status |
Regulatory Actions |
| 1994 |
FDA approval |
Flourishing sales as antidepressant |
Initial approval for treatment of major depressive disorder (MDD) |
| 2000s |
Increasing prescriptions |
Leading alternative to SSRIs |
Known for efficacy, but also reports of hepatotoxicity |
| 2004 |
FDA safety warning |
Rising safety concerns |
Warnings on hepatotoxicity; label revisions emphasizing liver monitoring |
| 2004 |
Market withdrawal |
Decline in sales |
Manufacturer Elan Pharmaceuticals ceased marketing in the U.S. |
| 2007 |
Product discontinuation |
Market withdrawal globally |
Eliminated from most markets, with limited remaining supplies |
Current Market Landscape
Nefazodone hydrochloride is no longer marketed in the United States, Europe, or other major markets. It retains limited, niche use where prescribed informally or off-label, and certain compounding pharmacies supply it in some regions.
Global Market Size
- Sales volume: Estimated at less than USD 10 million annually (pre-2004 peak), with current actual sales near negligible.
- Market share: Virtually zero in current therapeutic options.
Key Drivers and Barriers
Drivers:
- Historical efficacy as an antidepressant
- Alternative for patients intolerant of SSRIs or SNRIs
Barriers:
- Hepatotoxicity risk leading to regulatory restrictions
- Safety profile concerns resulting in market withdrawal
- Lack of recent clinical trials and R&D
R&D Landscape and Patent Status
Nefazodone’s patent expired decades ago, with no recent formulation patent protections. The absence of new formulations or combinations limits innovation prospects.
Financial Trajectory Analysis
| Period |
Sales (USD million) |
Growth/Decline |
Key Factors |
| 1994-2004 |
USD 150-200 |
Growth |
Rising prescriptions, market acceptance |
| 2004-2007 |
Decline to near zero |
Sharp decline |
Safety warnings, regulatory actions |
| 2008-present |
Minimal (~USD 1-5 annually) |
Stable/declining |
Limited, off-label use, compounding availability |
Projected sales over the next five years remain flat or decline further, with negligible market activity expected absent new approvals or formulations. Any market resurgence would require extensive safety data and regulatory approval, unlikely given current safety concerns.
Investment and R&D Outlook
Investments in nefazodone hydrochloride are dead. Companies focus on newer, safer antidepressants with fewer adverse effects. No active clinical trials or licensing agreements exist. Developers in psychiatric therapeutics have pivoted to agents with better safety profiles.
Competitive Landscape
- Major competitors: SSRIs, SNRIs, atypical antidepressants
- Market trends: Increased focus on safety, tolerability, personalized medicine
- Nefazodone’s future: Limited to historical context and potential niche off-label use
Regulatory Environment Impact
The safety concerns around nefazodone hydrochloride have resulted in:
- Removal from the market in key jurisdictions
- Strict prescribing restrictions where permitted
- Absence of regulatory pathways for approval of generics or new formulations
Conclusion
Nefazodone hydrochloride’s market is effectively dormant post-2007. Its financial trajectory remains stagnant, with negligible sales and no active R&D. Regulatory and safety barriers prevent revival. Any future market activity hinges on new safety data, innovation, or revised regulatory approvals, which are unlikely absent significant breakthroughs.
Key Takeaways
- Nefazodone hydrochloride peaked in sales in the late 1990s, then declined sharply after safety warnings in 2004.
- Presently, no commercial market exists for nefazodone, with minimal sales driven by residual, informal, or compounding pharmacy activity.
- The drug's patent expired long ago, with no active R&D or clinical development.
- Regulatory and safety concerns substantially limit future market potential.
- No near-term prospects for market resurgence or investment opportunities.
FAQs
1. Is nefazodone hydrochloride available in any form today?
Limited supplies may exist via compounding pharmacies in some regions, but it is not officially marketed or approved elsewhere.
2. Are there ongoing clinical trials involving nefazodone?
No. The last relevant clinical studies ended before 2010, with no active trials registered currently.
3. Can nefazodone be prescribed legally today?
In most markets, prescribing is restricted or prohibited due to safety concerns. Some regions may permit off-label use, but this is rare.
4. What safety issues are linked to nefazodone?
Hepatotoxicity remains the primary concern, leading to warnings and market withdrawal.
5. What are the alternative antidepressants replacing nefazodone?
SSRIs (e.g., sertraline, escitalopram), SNRIs (e.g., venlafaxine, duloxetine), and newer agents with improved safety profiles.
References
[1] Food and Drug Administration. (2004). Serzone (nefazodone): Drug safety information. FDA.
[2] Elan Pharmaceuticals. (2007). Market withdrawal notice for nefazodone. Public statement.
[3] IMS Health. (2004). Antidepressant market sales data.
[4] U.S. Patent and Trademark Office. (2022). Patent expiry records for nefazodone.
